ARTICLE | Data Byte
Comparing Point and Novartis radiopharmaceuticals readouts
The manufacturing-focused radiopharma met its primary endpoint but fell short of Novartis on rPFS; both companies face the same OS challenge
December 19, 2023 2:31 AM UTC
Point’s Phase III radiotherapy data, highly anticipated in the wake of its $1.4 billion Lilly deal, met its primary endpoint but fell short of both investor expectations and Novartis’ data in a similar setting, though the companies face the same hurdles to showing overall survival benefit.
Shares of Point Biopharma Global Inc. (NASDAQ:PNT) fell 11% to $12.45 Monday after the company and partner Lantheus Holdings Inc. (NASDAQ:LNTH) announced top-line data from the Phase III SPLASH trial of the β particle-emitting radiotherapy 177Lu-PNT2002. ...